94: Targeted Focal Laser Ablation for Prostate Cancer – Michael Magnani

We are delighted to team up with Clinical Laserthermia Systems Americas this week for a groundbreaking episode where we dive into the world of cutting-edge medical technology and shed light on an emerging innovation that promises to revolutionize the management of prostate cancer!

CLS is a leading medical device company at the forefront of pioneering precise and effective interventional healthcare solutions. They have developed an innovative CLS thermal therapy system for image-guided focal laser ablation that spares healthy tissue while minimizing the debilitating side effects often associated with traditional treatments. This technology can even be administered by a urologist in an office setting, bringing hope and convenience to countless patients. 

We are honored to have Michael Magnani, the President of CLS, joining us today to explore their new thermal therapy system for image-guided focal laser ablation. With a career spanning over two decades in corporate management within the life sciences industry, he brings a wealth of expertise in product development, corporate strategy, business development, and commercialization. He graduated from the unique Biomedical Enterprise Program at the MIT Sloan School of Management and holds a Bachelor of Science in Microbiology from the University of California, San Diego. 

Join us to learn about the exciting possibilities this transformative new technology holds for the future of prostate cancer management!

Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation.

Show highlights:

• .css-j9qmi7{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;font-weight:700;margin-bottom:1rem;margin-top:2.8rem;width:100%;-webkit-box-pack:start;-ms-flex-pack:start;-webkit-justify-content:start;justify-content:start;padding-left:5rem;}@media only screen and (max-width: 599px){.css-j9qmi7{padding-left:0;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}}.css-j9qmi7 svg{fill:#27292D;}.css-j9qmi7 .eagfbvw0{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;color:#27292D;}